AstraZeneca | Ophthalmology | 2024
The Company Franchise Analysis (CFA) provides a comprehensive evaluation of the franchise, including benchmarking, strategic insights, and an overview of marketed products. It highlights key market drivers and offers a detailed pipeline and sales analysis, along with information on deals and significant events. This profile aims to deliver a thorough understanding of the market dynamics and the strategic positioning of the franchise’s drugs.
Related Market Assessment Reports
Report
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Macular Edema (US)
Diabetic macular edema (DME) is a serious complication of diabetic retinopathy caused by persistently elevated blood glucose levels. Without timely treatment, DME can progress to significant vision…
Report
Uveitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Noninfectious Uveitis–Posterior Segment
Most vision loss from uveitis stems from persistent inflammation in the posterior segment of the eye. While noninfectious anterior uveitis is usually managed effectively with topical steroids,…
Report
Dry and Wet Age-Related Macular Degeneration – Current Treatment – Treatment Algorithms: Claims Data Analysis – Wet Age-Related Macular Degeneration (US)
The U.S. market for wet age-related macular degeneration (wet AMD) is in transition as newer therapies, including biosimilars, increasingly enter the treatment algorithm. While intravitreal options…
